The troubled development path of Alteon Inc.'s lead candidate alagebrium came to a temporary stop in two indications, after an interim look at Phase IIb data showed the drug failed to work against systolic hypertension, and the FDA put on clinical hold a Phase IIa trial with the same compound as a therapy for erectile dysfunction in diabetics. (BioWorld Today)